Aggressive GH Stack: GHRP-2 + CJC-1295 — Potency, Side Effects & Protocol

Introduction

The Aggressive GH Stack combines GHRP-2 (Growth Hormone-Releasing Peptide-2) and CJC-1295 (no DAC) for maximal growth hormone secretion. Unlike the more conservative GH Pulse Stack (which uses Ipamorelin), this protocol employs GHRP-2—a more potent ghrelin receptor agonist with higher cortisol and prolactin side effects.

Target audience: Experienced research participants willing to tolerate elevated cortisol and prolactin for maximum GH amplification.

Mechanism of Action

GHRP-2: Potent but “Dirty” Ghrelin Agonist

GHRP-2 is a hexapeptide (His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2) synthetic ghrelin receptor agonist. Unlike Ipamorelin, GHRP-2 has broad endocrine activation:

Primary Effect: GHS-R1a Activation

Robust pituitary somatotroph stimulation → strong GH secretion
Ghrelin-independent activation (GHRP-2 has its own receptor specificity, but GHS-R1a is primary)
Marked appetite stimulation (hypothalamic ghrelin-signaling activation)

Secondary Effects (Distinguishes GHRP-2 from Ipamorelin):

Cortisol elevation: GHRP-2 directly stimulates pituitary corticotrophs (ACTH release) → elevation of adrenal cortisol
- Acute dose: 100–300% cortisol increase (1–2 hours post-injection)
- Chronic dosing: Sustained mild-to-moderate elevation
- Implication: Catabolic effects, immune suppression, sleep disruption at high doses
Prolactin elevation: Direct lactotroph stimulation (poorly understood mechanism)
- Acute elevation: 50–100% increase
- Chronic effect: Mild gynecomastia risk, sexual dysfunction risk (males)
Hunger/Ghrelin surge: Much more pronounced than Ipamorelin
- Intense appetite stimulation within 15–30 minutes post-injection
- Can be leveraged for high-calorie research protocols; problematic for appetite-control goals

CJC-1295 (no DAC): GHRH Analog

(See prior article on GH Pulse Stack for full mechanism; included here for completeness)

GHRH analog → potentiates pituitary somatotroph responsiveness
Synergizes with GHRP-2’s ghrelin agonism
Half-life ~2–4 hours (SC); pulsatile dosing preferred

GHRP-2 + CJC-1295 Synergy: “Maximum GH”

Pituitary amplification:

GHRP-2 (ghrelin-R) + CJC-1295 (GHRH-R) activate overlapping but distinct somatotroph pathways
Combined activation produces GH secretion 4–10× baseline (animal/observational data)
Trade-off: Comes with cortisol/prolactin co-elevation

Comparative potency (preclinical models):

Ipamorelin + CJC-1295: GH amplification 4–8×, minimal cortisol/prolactin
GHRP-2 + CJC-1295: GH amplification 6–10×, significant cortisol/prolactin elevation

Key Research Data

Study	Year	Design	Key Finding
Arvat E et al.	1997	Human acute dosing	GHRP-2 + GHRH: GH peak 10–12× baseline; acute cortisol & ACTH elevation proportional; J Clin Endocrinol Metab
Sigalos JT & Pastuszak AW	2018	Review: GHS safety & efficacy	GHRP-2 more potent than Ipamorelin for GH; cortisol elevation significant; prolactin risk noted; Sex Med Rev, PMID: 29126857
Bodart V et al.	1999	Comparative GHS receptor profile	GHRP-2 > GHRP-6 > Ipamorelin for GH amplitude; GHRP compounds stimulate both GHS-R1a and off-target receptors (cortisol, prolactin)
Locatelli V & Torsello A	2006	GHS mechanisms in aging	GHRP-2 robust GH pulse generation in older adults; cortisol/prolactin side effects more pronounced with age

Protocol Details

Dosing & Administration

GHRP-2:

Dose: 200 mcg per injection
Frequency: 2–3× daily (morning, midday, evening)
Route: Subcutaneous
Timing: Fasted preferred (intensifies GH response; also intensifies appetite, which is unavoidable)
Half-life: ~30 minutes; pulsatile dosing pattern (not sustained elevation)

CJC-1295 (no DAC):

Dose: 200 mcg per injection (matched with GHRP-2)
Frequency: 2–3× daily (same timing as GHRP-2)
Route: Subcutaneous
Half-life: ~2–4 hours

Injection Timing Strategy

Optimal window for GH amplification:

Timing	Rationale	Notes
Morning (fasted)	Aligns with natural cortisol peak; maximizes hunger stimulus for feeding window	Intense appetite; plan meal within 30 min
Midday	Secondary GH pulse opportunity; space 6+ hours from other doses	Manageable appetite; less cortisol carry-over
Evening/Pre-sleep	Synergizes with natural nocturnal GH secretion; sleep aids GH consolidation	Cortisol elevation may impair sleep quality (caution)

Reconstitution

GHRP-2 (5 mg vial example):

Reconstitute with 5 mL sterile bacteriostatic water
Concentration: 1 mg/mL = 1,000 mcg/mL
Per 200 mcg dose: 20 units on U-100 insulin syringe

CJC-1295 (no DAC) (2 mg vial example):

Reconstitute with 2 mL bacteriostatic water
Concentration: 1 mg/mL
Per 200 mcg dose: 20 units on U-100 syringe

Cycling

Due to increased risk of receptor desensitization and cortisol burnout:

On-cycle: 4–6 weeks (shorter than Ipamorelin protocols due to side effect burden)
Off-cycle: 1–3 weeks minimum (longer recovery for HPA axis)
Annual duration: 8–16 weeks total GHRP-2 use per year (recommended limit)

Extending beyond 6 weeks continuous use risks:

GHS-R1a downregulation (reduced GH response)
Chronic cortisol elevation → fatigue, immune suppression, cortisol resistance
Sleep quality degradation

GH Response Dynamics

Acute Response (Single Dose)

Baseline GH ~0.5–2 ng/mL → Within 15–30 minutes post-GHRP-2 + CJC-1295:

GH peak: 15–50 ng/mL (highly variable; age, BMI, fitness dependent)
Duration: 2–4 hours above baseline
Cortisol: Acute elevation 100–300% (parallel to GH)

Chronic Response (Weekly Dosing)

Baseline IGF-1: Modest increases if protocols continue 6+ weeks (10–20% above baseline typical)
GH amplitude: Gradually blunts over 4–6 weeks (receptor desensitization)
Cortisol cumulative elevation: Average +20–40% if dosed 2–3× daily for 4 weeks

Synergies & Stacking Considerations

Why GHRP-2 Over Ipamorelin?

GHRP-2 is chosen by researchers seeking:

Maximum acute GH pulse (willing to accept side effects)
Intense appetite stimulus for high-calorie research (muscle gain protocols)
Rapid GH assessment (GHRP-2 response is predictable; useful for GH status testing)

Ipamorelin is preferred for:

Long-term use without cortisol burden
Sleep quality preservation
Cleaner side effect profile

Complementary Additions

Sleep protocol: Melatonin, magnesium glycinate to mitigate cortisol-driven sleep disruption
Anti-cortisol support: Phosphatidylserine (100–300 mg pre-bed) may blunt evening cortisol (modest evidence)
Caloric surplus: GHRP-2’s hunger is leveraged for muscle-building protocols; 500–1,000 kcal surplus recommended
Resistance training: GH is anabolic only in context of mechanical stimulus; daily strength work maximizes effect

Avoid Combination With

Daily corticosteroids: Additive cortisol elevation; health risk
Stimulants (high-dose caffeine, ephedrine): Synergistic cortisol elevation; sleep/anxiety risk
Chronic sleep deprivation: Cortisol elevation + poor sleep = metabolic dysfunction
Excessive alcohol: Blunts GH secretion; antagonizes GHRP-2 effect
Ipamorelin/CJC-1295 (simultaneous): Redundant GH stimulation; higher side effect risk without proportional benefit

Safety & Side Effects

Cortisol Elevation: The Primary Concern

GHRP-2’s main distinguishing feature is cortisol co-activation, which carries several implications:

Acute cortisol elevation (post-injection):

Hyperglycemia (cortisol is anti-insulin)
Anxiety/nervousness (15–30 min post-injection)
Potential appetite-suppressant phase (cortisol = catabolic) after GH-driven appetite surge

Chronic cortisol elevation (4–6 weeks dosing):

Catabolic state: Paradoxical muscle catabolism if caloric intake inadequate
Immune suppression: Increased infection risk; delayed wound healing
Sleep architecture disruption: Shallower REM sleep, earlier wake time
Mood effects: Anxiety, irritability, mood lability
Metabolic: Insulin resistance (mild–moderate), glucose intolerance
Musculoskeletal: Increased osteoporosis risk if chronic use repeated annually

Prolactin Elevation

Males: Gynecomastia risk (10–20% of chronic users); erectile dysfunction; reduced libido
Females: Galactorrhea, menstrual irregularity
Mitigation: Prolactin monitoring (serum prolactin level); if elevated >30 ng/mL, consider dopamine agonist (bromocriptine, cabergoline) or discontinue
Duration: Prolactin typically normalizes 1–2 weeks post-cessation

Appetite / GI Effects

Intense hunger: Often described as “uncontrollable” appetite spike within 15 min post-injection
GI distress: Nausea (rare); diarrhea (occasional with repeated dosing)
Carbohydrate cravings: Cortisol-driven preference for refined carbs
Mitigation: Plan meals immediately post-injection; protein/fat emphasis to stabilize glucose

Receptor Desensitization

GHS-R1a downregulation: Chronic GHRP-2 dosing blunts GH response over 4–6 weeks
Mechanism: Receptor internalization and reduced sensitivity
Clinical observation: Week 1–2 = robust GH response; Week 4–6 = declining response
Mitigation: Cycling (4–6 weeks on, 2–3 weeks off) restores sensitivity

Rarer Serious Adverse Events

Carpal tunnel syndrome: Acromegaly-like symptoms (edema, median nerve compression); risk increases with 2–3× daily dosing >8 weeks. Reported in ~1–5% of long-term GHRP-2 users.
Hypertension: GH elevation can raise BP; GHRP-2’s additional cortisol effect amplifies this. Baseline BP monitoring essential.
Hyperglycemia/Diabetes risk: Cortisol + GH both antagonize insulin. Acute hyperglycemia common; risk of type 2 diabetes with repeated cycles in susceptible individuals.
Joint pain/fluid retention: GH-driven water accumulation (typically benign, 2–5 lbs over 4 weeks); can worsen existing joint pain due to edema.

Contraindications

Absolute:

Uncontrolled hypertension (SBP >160)
Uncontrolled diabetes or insulin resistance
Severe depression or mood disorder (cortisol elevation worsens these)
Active infection/immune compromise
Adrenal insufficiency or severe HPA axis dysfunction
Pregnancy (GH is teratogenic; cortisol elevation harmful)

Relative (require monitoring):

Diabetes: Intensive glucose monitoring; increased hypoglycemia/hyperglycemia risk
Sleep apnea: GHRP-2 may worsen; sleep study advised
Hypertension (controlled): Monthly BP checks
Mental health history: Mood monitoring; cytisol elevation may trigger anxiety/depression

GHRP-2 vs. Ipamorelin: Direct Comparison

Feature	GHRP-2 + CJC-1295	Ipamorelin + CJC-1295
GH Amplification	6–10×	4–8×
Cortisol Elevation	Significant	Minimal
Prolactin Elevation	Moderate–High	None/minimal
Appetite Stimulation	Intense (“uncontrollable”)	Mild
Sleep Impact	Often impaired	Usually preserved
Long-term Use	4–6 weeks max	8–12 weeks tolerable
Side Effect Burden	Higher	Lower
Best For	Maximum GH + high-calorie protocol	Long-term GH support with side effect minimization

Research Disclaimer

All information in this article is provided for research and educational purposes only. GHRP-2 is not approved by regulatory agencies (FDA, EMA) for human use. This content does not constitute medical advice.

GHRP-2 carries significant endocrine side effects (cortisol, prolactin) that require medical supervision. Researchers considering GHRP-2 protocols must:

Consult qualified endocrinologists experienced with GHS peptides
Undergo baseline testing: cortisol (24-hour UFC or AM serum), prolactin, glucose, BP, testosterone (males)
Monitor actively: Bi-weekly cortisol & prolactin during on-cycle; weekly if symptoms emerge
Limit use to 4–6 weeks per cycle, with 2–3 week off-cycles minimum
Stop immediately if severe mood changes, uncontrolled hypertension, or hyperglycemia occur
Obtain peptides from verified, tested sources (contamination/mislabeling risk)

GHRP-2 is most appropriate for short-term, goal-specific research (e.g., 8-week muscle-building protocol) rather than indefinite use. Individual tolerance varies significantly based on age, genetics, and baseline metabolic health.